Condition
Advanced Solid Tumour clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Advanced Solid Tumour clinical trials that are recruiting, at sites in 6 countries (most in China (4), Belgium (1), France (1)). By phase: Phase 2 (4), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 6Countries
Newest Advanced Solid Tumour clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Testing different doses of BI 3968621 alone or with ezabenlimab in adults with advanced cancer | Phase 1 | Sarasota, Florida and 9 other locations | Recruiting | Oct 1, 2026 |
| LBL-024 combined with chemotherapy and immunotherapy for advanced gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Beijing, Beijing Municipality and 6 other locations | Recruiting | Feb 5, 2026 |
| LBL-024 combination treatment for advanced esophageal squamous cell carcinoma (Phase II, Substudy 03) | Phase 2 | Beijing, Beijing Municipality and 6 other locations | Recruiting | Jan 9, 2026 |
| LBL-024 combined treatment for advanced biliary tract cancer and hepatocellular carcinoma. | Phase 2 | Hefei, Anhui and 15 other locations | Recruiting | Aug 8, 2025 |
| LBL-024 combination therapy for advanced non-small cell lung cancer (NSCLC) | Phase 2 | Hefei, Anhui and 23 other locations | Recruiting | Jan 20, 2025 |
All recruiting trials (5)
-
Testing different doses of BI 3968621 alone or with ezabenlimab in adults with advanced cancer
This study tests whether BI 3968621, alone or with ezabenlimab, can be given safely at different doses to adults with advanced solid tumors and whether it can slow or shrink tumors.
-
LBL-024 combined with chemotherapy and immunotherapy for advanced gastric or gastroesophageal junction adenocarcinoma
This study will test whether adding LBL-024 to capecitabine, oxaliplatin, and tislelizumab helps adults with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
LBL-024 combination treatment for advanced esophageal squamous cell carcinoma (Phase II, Substudy 03)
This trial tries LBL-024 combined with chemotherapy and immunotherapy in adults with advanced esophageal squamous cell carcinoma to see if it better controls tumors or prolongs benefit.
-
LBL-024 combined treatment for advanced biliary tract cancer and hepatocellular carcinoma.
This study tests whether LBL-024 given with chemotherapy and bevacizumab helps adults with advanced biliary tract cancer or hepatocellular carcinoma.
-
LBL-024 combination therapy for advanced non-small cell lung cancer (NSCLC)
This study tests whether adding LBL-024 to chemotherapy or other cancer drugs helps people with advanced NSCLC respond better or live longer.
Related topics
Quick answers
How many Advanced Solid Tumour clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in China (4 trials), Belgium (1 trial), France (1 trial), Japan (1 trial), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.